Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 17,519 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 17,519 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $37.30, for a total value of $653,458.70. Following the transaction, the insider directly owned 18,630,739 shares in the company, valued at $694,926,564.70. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The shares were sold at an average price of $36.48, for a total transaction of $5,280,698.88.
• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The shares were sold at an average price of $37.17, for a total transaction of $6,426,655.83.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Trading Down 1.5%

Shares of ROIV stock opened at $36.30 on Friday. The company has a market capitalization of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12. The firm has a fifty day simple moving average of $34.61 and a 200-day simple moving average of $30.43. Roivant Sciences Ltd. has a twelve month low of $11.60 and a twelve month high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Equities research analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current year.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after purchasing an additional 376 shares during the last quarter. Bessemer Group Inc. increased its holdings in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its stake in Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares in the last quarter. Versant Capital Management Inc raised its stake in Roivant Sciences by 13.9% during the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock valued at $141,000 after buying an additional 487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after buying an additional 500 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Citigroup raised their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.